Trivium Point Advisory’s Amgen AMGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.26M | Buy |
3,478
+602
| +21% | +$206K | 0.11% | 164 |
|
|
2026
Q1 | $1.01M | Sell |
2,876
-583
| -17% | -$208K | 0.18% | 129 |
|
|
2025
Q4 | $1.13M | Sell |
3,459
-361
| -9% | -$115K | 0.11% | 167 |
|
|
2025
Q3 | $1.08M | Buy |
3,820
+223
| +6% | +$64.7K | 0.11% | 171 |
|
|
2025
Q2 | $1M | Sell |
3,597
-11,007
| -75% | -$3.12M | 0.11% | 172 |
|
|
2025
Q1 | $4.55M | Sell |
14,604
-606
| -4% | -$179K | 0.56% | 50 |
|
|
2024
Q4 | $3.96M | Buy |
15,210
+189
| +1% | +$56.1K | 0.5% | 55 |
|
|
2024
Q3 | $4.53M | Sell |
15,021
-1,613
| -10% | -$528K | 0.63% | 40 |
|
|
2024
Q2 | $5.2M | Buy |
16,634
+845
| +5% | +$248K | 0.77% | 30 |
|
|
2024
Q1 | $4.49M | Buy |
15,789
+1,955
| +14% | +$572K | 0.97% | 27 |
|
|
2023
Q4 | $3.98M | Buy |
13,834
+2,750
| +25% | +$749K | 0.97% | 27 |
|
|
2023
Q3 | $2.89M | Buy |
11,084
+10,166
| +1,107% | +$2.54M | 0.8% | 32 |
|
|
2023
Q2 | $204K | Sell |
918
-39
| -4% | -$9.05K | 0.06% | 186 |
|
|
2023
Q1 | $231K | Sell |
957
-22
| -2% | -$5.4K | 0.06% | 175 |
|
|
2022
Q4 | $269K | Sell |
979
-16
| -2% | -$4.29K | 0.08% | 160 |
|
|
2022
Q3 | $230K | Sell |
995
-29
| -3% | -$7.03K | 0.07% | 167 |
|
|
2022
Q2 | $253K | Sell |
1,024
-23
| -2% | -$5.64K | 0.08% | 173 |
|
|
2022
Q1 | $262K | Buy |
1,047
+61
| +6% | +$14K | 0.06% | 198 |
|
|
2021
Q4 | $222K | Sell |
986
-111
| -10% | -$23.4K | 0.05% | 219 |
|
|
2021
Q3 | $229K | Sell |
1,097
-31
| -3% | -$7.13K | 0.05% | 204 |
|
|
2021
Q2 | $275K | Sell |
1,128
-3
| -0.3% | -$738 | 0.07% | 186 |
|
|
2021
Q1 | $281K | Sell |
1,131
-28
| -2% | -$6.68K | 0.08% | 173 |
|
|
2020
Q4 | $271K | Sell |
1,159
-34
| -3% | -$7.84K | 0.08% | 168 |
|
|
2020
Q3 | $303K | Sell |
1,193
-52
| -4% | -$12.9K | 0.11% | 141 |
|
|
2020
Q2 | $319K | Sell |
1,245
-340
| -21% | -$77.6K | 0.13% | 134 |
|
|
2020
Q1 | $347K | Buy |
1,585
+235
| +17% | +$51.3K | 0.18% | 115 |
|
|
2019
Q4 | $325K | Buy |
1,350
+3
| +0.2% | +$661 | 0.13% | 132 |
|
|
2019
Q3 | $265K | Buy |
1,347
+16
| +1% | +$3.07K | 0.12% | 137 |
|
|
2019
Q2 | $245K | Hold |
1,331
| – | – | 0.11% | 143 |
|
|
2019
Q1 | $253K | Sell |
1,331
-58
| -4% | -$11.1K | 0.12% | 139 |
|
|
2018
Q4 | $270K | Buy |
+1,389
| New | +$271K | 0.16% | 123 |
|
Other funds holding AMGN
Trivium Point Advisory's AMGN Position: Q2 2026 in Review
Trivium Point Advisory increased its Amgen (AMGN) stake by 21% in Q2 2026, buying an estimated $206K and bringing the position to 3,478 shares worth $1.26M. The position accounts for 0.11% of the portfolio, ranked #164.
Trivium Point Advisory first reported a position in AMGN in Q4 2018 and has held it in 31 quarters since. The position peaked at $5.2M in Q2 2024. 3,164 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.
- Trivium Point Advisory held 3,478 shares of Amgen worth $1.26M as of Q2 2026.
- Trivium Point Advisory bought 602 Amgen shares in Q2 2026, an estimated $206K.
- Amgen made up 0.11% of Trivium Point Advisory's portfolio in Q2 2026, its #164 holding.
- Trivium Point Advisory first reported a position in Amgen in Q4 2018 and has held it in 31 quarters since.
- Trivium Point Advisory's Amgen position peaked at $5.2M in Q2 2024.
- 3,164 funds tracked by Wall St. Rank held Amgen as of Q2 2026.
Based on Trivium Point Advisory's 13F filing for Q2 2026, filed 6 Aug 2026.